VeracyteVCYT
VCYT
About: Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Employees: 824
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
2.61% more ownership
Funds ownership: 105.87% [Q4 2024] → 108.48% (+2.61%) [Q1 2025]
4% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 106
8% less call options, than puts
Call options by funds: $515K | Put options by funds: $557K
10% less funds holding
Funds holding: 316 [Q4 2024] → 283 (-33) [Q1 2025]
23% less capital invested
Capital invested by funds: $3.25B [Q4 2024] → $2.51B (-$741M) [Q1 2025]
40% less funds holding in top 10
Funds holding in top 10: 5 [Q4 2024] → 3 (-2) [Q1 2025]
54% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 56
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$37
40%
upside
Avg. target
$42
59%
upside
High target
$45
70%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
UBS Lu Li | 59%upside $42 | Buy Maintained | 8 May 2025 |
Needham Mike Matson | 55%upside $41 | Buy Maintained | 8 May 2025 |
Guggenheim Subbu Nambi | 40%upside $37 | Buy Maintained | 9 Apr 2025 |
Stephens & Co. Mason Carrico | 70%upside $45 | Overweight Reiterated | 26 Mar 2025 |
Craig-Hallum John Wilkin | 70%upside $45 | Buy Initiated | 20 Mar 2025 |
Financial journalist opinion
Based on 3 articles about VCYT published over the past 30 days
Neutral
Business Wire
2 weeks ago
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance Prostate and Bladder Cancer Research.
Neutral
Business Wire
3 weeks ago
Veracyte to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. William Blair 45th Annual Growth Stock Conference – Chicago, IL Presentation on June 3rd at 5:40 p.m. Eastern Time Jefferies Global Healthcare Conference – New York, NY Presentation on June 4th at 2:00 p.m. Eastern Time Live audio webcasts of the company's presentations will be available by visiting Veracyte'.
Positive
Zacks Investment Research
3 weeks ago
Veracyte Stock Surges 30.9% in a Year: What's Driving the Rally?
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
Positive
Zacks Investment Research
1 month ago
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests in the first quarter of 2025.
Positive
Zacks Investment Research
1 month ago
What Makes Veracyte (VCYT) a New Buy Stock
Veracyte (VCYT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Neutral
Seeking Alpha
1 month ago
Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript
Veracyte, Inc. (NASDAQ:VCYT ) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants Shayla Gorman - Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer John Leite - Chief Commercial Officer Conference Call Participants Subbu Nambi - Guggenheim Securities Andrew Brackmann - William Blair Puneet Souda - Leerink Partners Colleen Babington - Wolfe Research Tejas Savant - Morgan Stanley Thomas DeBourcy - Nephron Research Sung Ji Nam - Scotiabank Operator Good day and thank you for standing by. Welcome to the Veracyte First Quarter 2025 Financial Results Webcast.
Positive
Zacks Investment Research
1 month ago
Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates
Veracyte (VCYT) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.20 per share. This compares to loss of $0.02 per share a year ago.
Neutral
Business Wire
1 month ago
Veracyte Announces First Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand,” said Marc Stapley, Veracyte's chief executive officer. “With solid Q1 results and Decipher now available for metastatic prostate cancer patients, we are well positione.
Neutral
Business Wire
1 month ago
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer.
Neutral
Business Wire
1 month ago
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing Will Be Presented at AUA Annual Meeting.
Charts implemented using Lightweight Charts™